Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994532 | 0.87 | MEN1 (0.35) | CYP3A4LPAR3LPAR2LPAR1ALDH1A1 | |
| SCHEMBL9067973 | 0.83 | CYP3A4 (0.52) | CYP3A4LPAR3LPAR2LPAR1ALDH1A1 | |
| SCHEMBL17860875 | 0.82 | CYP3A4 (0.50) | CYP3A4LPAR3LPAR2LPAR1ALDH1A1 | |
| SCHEMBL15951693 | 0.80 | CYP3A4 (0.48) | CYP3A4LPAR3LPAR2LPAR1ALDH1A1 | |
| SCHEMBL2238085 | 0.80 | CYP3A4 (0.48) | CYP3A4LPAR3LPAR2LPAR1ALDH1A1 | |
| SCHEMBL15951705 | 0.79 | CYP3A4 (0.47) | CYP3A4LPAR3LPAR2LPAR1ALDH1A1 | |
| SCHEMBL17878594 | 0.79 | CYP3A4 (0.47) | CYP3A4LPAR3LPAR2LPAR1ALDH1A1 | |
| SCHEMBL28916156 | 0.79 | CYP3A4 (0.47) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL2354042 | 0.79 | CYP3A4 (0.47) | CYP3A4LPAR3LPAR2LPAR1ALDH1A1 | |
| SCHEMBL11645517 | 0.79 | CYP3A4 (0.47) | CYP3A4LPAR3LPAR2LPAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | UBE INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | UBE INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | HCN2, SCO2, HCN1 | CYP3A4 3376/4885LPAR3 2391/4885LPAR2 1392/4885 |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | VIP, AQP1, PEF1 | CYP3A4 3756/4885LPAR3 2783/4885LPAR2 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.